Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status

International Journal of Surgical Pathology

Volumn 19, Issue 6, 2011, Pages 751-760

  Kevans, David ^a   Wang, Lai Mun ^a   Sheahan, Kieran ^a   Hyland, John ^a   O'Donoghue, Diarmuid ^a   Mulcahy, Hugh ^a   O'Sullivan, Jacintha ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

epithelial mesenchymal transition; mismatch repair proteins; survival; tumor budding

Indexed keywords

BETA CATENIN; CATHEPSIN L; LAMININ; LAMININ GAMMA2; MISMATCH REPAIR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR BUDDING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CATHEPSIN L; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IRELAND; LAMININ; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860229851     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896911414566     Document Type: Article

References (38)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001 ; 51: 15-36 (Pubitemid 32166444)
2. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut. 2002 ; 51: 65-69 (Pubitemid 34717746)
3. Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007 ; 50: 151-162 (Pubitemid 44953405)
4. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009 ; 33: 134-141
5. Goldstein NS, Hart J. Histologic features associated with lymph node metastasis in stage T1 and superficial T2 rectal adenocarcinomas in abdominoperineal resection specimens: Identifying a subset of patients for whom treatment with adjuvant therapy or completion abdominoperineal resection should be considered after local excision. Am J Clin Pathol. 1999 ; 111: 51-58 (Pubitemid 29024966)
6. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993 ; 36: 627-635 (Pubitemid 23206317)
7. Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008 ; 10: 41-47 (Pubitemid 350238562)
8. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 2003 ; 46: 1400-1406 (Pubitemid 37267636)
9. Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol. 2003 ; 83: 42-47 (Pubitemid 36528708)
10. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005 ; 47: 17-24 (Pubitemid 40978809)
11. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum. 2003 ; 46: 1054-1059 (Pubitemid 36992987)
12. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003 ; 3: 362-374 (Pubitemid 37328856)
13. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001 ; 23: 912-923 (Pubitemid 32972691)
14. Prall F, Weirich V, Ostwald C. Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC) gene. Histopathology. 2007 ; 50: 318-330 (Pubitemid 46169416)
15. Sobin LH, Wittekind C International Union Against Cancer: TNM Classification of Malignant Tumours. John Wiley: New York, NY ; 1997 :
16. Lugli A, Zlobec I, Minoo P, et al. Prognostic significance of the WNT signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology. 2007 ; 50: 453-464 (Pubitemid 46328181)
17. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol. 2002 ; 12: 197-207 (Pubitemid 34833063)
18. Shinto E, Tsuda H, Ueno H, et al. Prognostic implication of laminin-5 gamma 2 chain expression in the invasive front of colorectal cancers, disclosed by area-specific four-point tissue microarrays. Lab Invest. 2005 ; 85: 257-266 (Pubitemid 40208929)
19. Akimoto S, Nakanishi Y, Sakamoto M, Kanai Y, Hirohashi S. Laminin 5 beta3 and gamma2 chains are frequently coexpressed in cancer cells. Pathol Int. 2004 ; 54: 688-692 (Pubitemid 39297294)
20. Masaki T, Matsuoka H, Sugiyama M, et al. Laminin-5 gamma2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomas. Dig Dis Sci. 2003 ; 48: 272-278 (Pubitemid 36232991)
21. Masaki T, Sugiyama M, Matsuoka H, et al. Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas. Dig Dis Sci. 2003 ; 48: 1262-1267 (Pubitemid 36793902)
22. Kim TD, Song KS, Li G, et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer. 2006 ; 6: 211
23. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 1995 ; 55: 4132-4139
24. Sheahan K, Shuja S, Murnane MJ. Cysteine protease activities and tumor development in human colorectal carcinoma. Cancer Res. 1989 ; 49: 3809-3814 (Pubitemid 19197402)
25. Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol. 1990 ; 1: 127-136
26. Hlubek F, Spaderna S, Schmalhofer O, Jung A, Kirchner T, Brabletz T. Wnt/FZD signaling and colorectal cancer morphogenesis. Front Biosci. 2007 ; 12: 458-470 (Pubitemid 46852799)
27. Brabletz T, Hlubek F, Spaderna S, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005 ; 179: 56-65 (Pubitemid 40976289)
28. Suzuki H, Masuda N, Shimura T, et al. Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res. 2008 ; 28: 1821-1830 (Pubitemid 351892891)
29. Wong SC, Lo ES, Chan AK, Lee KC, Hsiao W. Nuclear beta catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. Mol Pathol. 2003 ; 56: 347-352 (Pubitemid 37521928)
30. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res. 2001 ; 7: 4013-4020 (Pubitemid 34044621)
31. Yu XW, Rong W, Xu FL, Xu GY, Sun YR, Feng MY. Expression and clinical significance of Mucin and E-cadherin in colorectal tumors [in Chinese]. Ai Zheng. 2007 ; 26: 1204-1210
32. Kwak JM, Min BW, Lee JH, et al. The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum. 2007 ; 50: 1873-1880
33. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Expression of cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer. 2004 ; 40: 1610-1616 (Pubitemid 38757752)
34. Sullivan S, Tosetto M, Kevans D, et al. Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer. Int J Cancer. 2009 ; 125: 54-61
35. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007 ; 50: 113-130 (Pubitemid 44953403)
36. Jass JR, Barker M, Fraser L, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol. 2003 ; 56: 69-73 (Pubitemid 36132478)
37. Kawasaki T, Nosho K, Ohnishi M, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia. 2007 ; 9: 569-577 (Pubitemid 47121831)
38. Ortega P, Moran A, de Juan C, et al. Differential WNT pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clin Cancer Res. 2008 ; 14: 995-1001 (Pubitemid 351302544)